Advanced therapeutic technologies for malaria, tuberculosis, HIV infection and neglected tropical diseases
| dc.contributor.author | Dube, Admire | |
| dc.contributor.author | Laverty, Garry | |
| dc.contributor.author | Balogun, Mohammed | |
| dc.date.accessioned | 2026-02-05T07:16:32Z | |
| dc.date.available | 2026-02-05T07:16:32Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | We are pleased to present this special issue to highlight advances in therapeutic technologies for infectious diseases, in particular for treatment of tuberculosis (TB), HIV/AIDS and malaria. Informative reviews as well as original research articles form part of this Issue. The world’s deadliest infectious diseases TB, HIV/AIDS and malaria are responsible for close to 2.5 million deaths world-wide, each year.[1] Over 90% of deaths due to malaria occur in subSaharan Africa, with the majority of deaths occurring in children under 5 years of age. Infectious diseases are responsible for ≈704 million disability-adjusted life-years (DALYs) and the African region bears the highest burden, with ≈314 million DALYs; while high-income countries account for only ≈31.8 million DALYs.[2] | |
| dc.identifier.citation | Dube, A., Laverty, G. and Balogun, M., 2025. Advanced therapeutic technologies for malaria, tuberculosis, HIV infection and neglected tropical diseases. Advanced Therapeutics, 8(4), p.2500115. | |
| dc.identifier.uri | https://doi.org/10.1002/adtp.202500115 | |
| dc.identifier.uri | https://hdl.handle.net/10566/21884 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc | |
| dc.subject | antibiotic agent | |
| dc.subject | drug carrier | |
| dc.subject | everolimus | |
| dc.subject | metal nanoparticle | |
| dc.subject | micelle (pharmaceutics) | |
| dc.title | Advanced therapeutic technologies for malaria, tuberculosis, HIV infection and neglected tropical diseases | |
| dc.type | Article |